ReviewCurrent opinion in neurology2012
Cochlear gene therapy.
Review in Current opinion in neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- AudioGene: refining the natural history of KCNQ4, GSDME, WFS1, and COCH-associated hearing loss.Human genetics · 2022Article
- Improving Control of Gene Therapy-Based Neurotrophin Delivery for Inner Ear Applications.Frontiers in bioengineering and biotechnology · 2022Article
- Neurotrophin gene therapy to promote survival of spiral ganglion neurons after deafness.Hearing research · 2020Review
- Development of in-house genetic screening for pediatric hearing loss.Laryngoscope investigative otolaryngology · 2020Article
- AAV-Mediated Neurotrophin Gene Therapy Promotes Improved Survival of Cochlear Spiral Ganglion Neurons in Neonatally Deafened Cats: Comparison of AAV2-hBDNF and AAV5-hGDNF.Journal of the Association for Research in Otolaryngology : JARO · 2019Article
- Neural crest contributions to the ear: Implications for congenital hearing disorders.Hearing research · 2019Review
- Virally Mediated Overexpression of Glial-Derived Neurotrophic Factor Elicits Age- and Dose-Dependent Neuronal Toxicity and Hearing Loss.Human gene therapy · 2019Article
- Transduction of Adeno-Associated Virus Vectors Targeting Hair Cells and Supporting Cells in the Neonatal Mouse Cochlea.Frontiers in cellular neuroscience · 2019Article
- Outlook and future of inner ear therapy.Hearing research · 2018Review
- Ototoxicity: A Challenge in Diagnosis and Treatment.Journal of audiology & otology · 2018Review
- Review
- Genetics of Nonsyndromic Congenital Hearing Loss.Scientifica · 2016Review
- The spread of adenoviral vectors to central nervous system through pathway of cochlea in mimetic aging and young rats.Gene therapy · 2015Article
- Comparing the cultivated cochlear cells derived from neonatal and adult mouse.Journal of translational medicine · 2014Article
- Investors start backing hearing loss treatments.Nature biotechnology · 2013Article
- Intracellular Delivery of Short Interfering RNA in Rat Organ of Corti Using a Cell-penetrating Peptide PepFect6.Molecular therapy. Nucleic acids · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThis review highlights recent advances in cochlear gene therapy over the past several years. Cochlear gene therapy has undergone tremendous advances over the past decade. Beginning with some groundbreaking work in 2005 documenting hair cell regeneration using virally mediated delivery of the mouse atonal 1 gene, gene therapy is now being explored as a possible treatment for a variety of causes of hearing loss. RECENT
findingsRecent advances in cochlear gene therapy include improved methods of gene delivery with a better delineation of viral vectors that are suitable for this purpose, additional improvements in hair cell regeneration, and directed research toward autoimmune hearing loss, ototoxicity, spiral ganglion survival, and genetic forms of hearing loss. SUMMARY: If successful, cochlear gene therapy will dramatically alter our ability to treat a variety of forms of acquired and genetic hearing loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.